Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer

[1]  K. Matsuo,et al.  Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy , 2011, Cancer Chemotherapy and Pharmacology.

[2]  K. Matsuo,et al.  Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  V. Gebski,et al.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yong-Man Kim,et al.  Is chemotherapy‐induced neutropenia a prognostic factor in patients with ovarian cancer? , 2010, Acta Obstetricia et Gynecologica Scandinavica.

[5]  K. Matsuo,et al.  Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. , 2009, European journal of cancer.

[6]  G. Rustin,et al.  Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Söderkvist,et al.  Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. , 2009, Basic & clinical pharmacology & toxicology.

[8]  S. Agelaki,et al.  Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. , 2008, Lung cancer.

[9]  M. Dimopoulos,et al.  Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. , 2008, Anticancer research.

[10]  K. Byth,et al.  ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy , 2008, Clinical Cancer Research.

[11]  M. Barnes,et al.  Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. , 2008, Gynecologic oncology.

[12]  H. Hollema,et al.  Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group , 2007, Clinical Cancer Research.

[13]  Robert Brown,et al.  Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Yamanaka,et al.  Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma , 2007, British Journal of Cancer.

[15]  S. Steinberg,et al.  Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. , 2006, European journal of cancer.

[16]  E. Eisenhauer,et al.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Robert Brown,et al.  ABCB1 2677G>T/A Genotype and Paclitaxel Pharmacogenetics in Ovarian Cancer , 2006, Clinical Cancer Research.

[18]  F. Goldwasser,et al.  Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms , 2006, Clinical pharmacology and therapeutics.

[19]  P. Söderkvist,et al.  mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy , 2006, Clinical Cancer Research.

[20]  Alan Richardson,et al.  Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[21]  C. Gridelli,et al.  Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials , 2005, BMC Cancer.

[22]  H. Gurney.  I don't underdose my patients...do I? , 2005, The Lancet. Oncology.

[23]  D. L. Le Couteur,et al.  The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[24]  G. Lyman,et al.  Chemotherapy‐induced neutropenia , 2004, Cancer.

[25]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Bergh,et al.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial , 2000, The Lancet.

[27]  C. Blomqvist,et al.  Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF , 1999, British Journal of Cancer.

[28]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Relling,et al.  Variability in human cytochrome P450 paclitaxel metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[30]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Eisenhauer,et al.  Clinical toxicities encountered with paclitaxel (Taxol). , 1993, Seminars in oncology.

[32]  P. Söderkvist,et al.  In response [2] , 2006 .

[33]  A. Auvinen,et al.  Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. , 1997, British Journal of Cancer.

[34]  R. Donehower,et al.  Neurotoxicity of Taxol. , 1993, Journal of the National Cancer Institute. Monographs.